FOXO4-DRI vs Vilon
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, FOXO4-DRI or Vilon?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between FOXO4-DRI and Vilon?
FOXO4-DRI has a defined molecular target and mechanism of action; vilon is a dipeptide with claimed immune effects but no well-characterized binding target or signaling pathway.
Evidence Comparison
FOXO4-DRI: published in Cell (Baar 2017) with defined molecular target (FOXO4-p53 interaction). Vilon: Khavinson dipeptide (Lys-Glu) with immune modulation claims, but minimal mechanistic characterization and all data from a single group. FOXO4-DRI has substantially better mechanistic evidence.
Evidence Context Favoring FOXO4-DRI
Research requiring a defined senolytic mechanism with published molecular target data.
Evidence Context Favoring Vilon
Khavinson bioregulator research paradigm exploring short peptide immune modulation - accepting the minimal mechanistic characterization.
Side-by-Side Snapshot
| Evidence grade | FOXO4-DRI: Level D Vilon: Level D |
|---|---|
| Research status | FOXO4-DRI: Preclinical Vilon: Early Research |
| Primary category | FOXO4-DRI: Anti-Aging & Longevity Vilon: Anti-Aging & Longevity |
| Cited studies | FOXO4-DRI: 2 Vilon: 2 |